// App-Quantinova.ai

OR1‐004 : Pooled data from 3 randomized phase 3 studies: 11q deletion (del11q) is not a prognostic factor for adverse outcomes for patients (pts) with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) treated with ibrutinib (Ibr)

Researchers

Presenter

  • A Janssens

Principal Investigators

  • P Hillmen

  • F Demirkan

  • S Grosicki

  • S Coutre

  • JC Barrientos

  • PM Barr

  • JC Byrd

  • SM O'Brien

  • G Fraser

  • U Jaeger

  • P Cramer

  • S Stilgenbauer

  • AA Chanan-Khan

  • M Salman

  • I Solman

  • M Cheng

  • C Phelps

  • J Ninomoto

  • A Howes

  • DF James

  • M Hallek

Medical Centers

  • Department of Hematology, University Hospital Leuven, Leuven, Belgium

  • UCSD, Moores Cancer center, La Jolla, United States

  • The Leeds Teaching Hospitals, St. James Institute of Oncology, Leeds, United Kingdom

  • Institute for Oncology, Dokuz Eylul University, Izmir, Turkey

  • Department of Cancer Prevention, School of Public Health, Silesian Medical University, Katowice, Poland

  • Divisions of Hematology and Oncology and Stanford Cancer Center, Stanford University School of Medicine, Stanford, CA

  • Division of Hematology and Medical Oncology, Department of Medicine, Hofstra Northwell School of Medicine, Hemstead, NY

  • James P. Wilmot Cancer Center, Department of Medicine, Hematology/Oncology, University of Rochester Medical Center, Rochester, NY

  • Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • University of California, Davis, Davis, California, United States

  • Department of Medical Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada

  • Division of Hematology and Hemostaseology, Medical University of Vienna, Wien, Austria

  • Department I of Internal Medicine and German CLL Study Group, University of Cologne, Cologne, Germany

  • Department of Internal Medicine, Division of Hematology, University of Ulm, Ulm, Germany

  • Division of Hematology, Mayo Clinic Cancer Center, Jacksonville, FL

  • Janssen Research & Development, LLC, Raritan, NJ

  • Pharmacyclics LLC, an AbbVie Company,Sunnyvale, CA, United States,United States

Locations

  • Belgium

  • United States

  • United Kingdom

  • Turkey

  • Poland

  • Canada

  • Austria

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Immunoglobulin heavy-chain variable region gene

Drug/Treatment

  • Bendamustine

  • chlorambucil

  • ofatumumab Intravenous

  • Ibrutinib

  • Rituximab

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved